Search

Displaying results 3221 - 3230 of 10000 in total
  1. Drug

    Lanolin

    go.drugbank.com/drugs/DB11112
    Approved

    Lanolin is a yellow fat obtained from sheep's wool. It is used as an emollient, cosmetic, and pharmaceutic aid [L2580]. … The US federal code of regulations states that lanolin in the concentration range of 12-50% may be included in over the counter skin ointments [L2583].

    Mixtures: Veradex-E, A D and L Original Diaper Rash SkinCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.

  3. Drug

    Arginine glutamate

    go.drugbank.com/drugs/DB13207
    Investigational

    Synonyms: L-Arginine L-glutamate, (2S)-2-amino-5-guanidino-pentanoic acid;(2S)-2-aminopentanedioic acidMixtures: Nutriflex peri Infusionslösung
  4. Drug

    Mometasone furoate

    go.drugbank.com/drugs/DB14512
    ApprovedInvestigationalVet approved

    Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295]. … Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295].

    Mixtures: M-FURO FA %0.1 + %2 KREM, 30 G, DERMOTIL-S® UNGUENTOCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: PADCEV 20 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ , 1 ADET, PADCEV 30 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ , 1 ADET
  6. Drug

    Camellia japonica seed oil

    go.drugbank.com/drugs/DB14308
    Investigational

    Camellia japonica seed oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Nail Care Pen
  7. Drug

    Clostridium tetani toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10583
    ApprovedInvestigational

    Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. … It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus.

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, 3 ANTIGENProducts: TETAVAX single dose, suspension for injection in a prefilled syringe, T-VAC 0,5 ML IM ENJEKSIYON IÇIN SÜSPANSIYON IÇEREN AMPUL
  8. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.

    Mixtures: ARAHKOR - PRECategories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting. … Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.

    Mixtures: COPHADYL-E COUGH LINCTUS, PROMEDYL-B LINCTUSCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). … [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval.

    Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Lymphocyte Activation Gene-3 Blocker